These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30396934)

  • 1. Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
    Kim HM; Jeong I; Kim HJ; Kang SK; Kwon WS; Kim TS; Park KH; Jung M; Soong J; Lin SC; Chung HC; Rha SY
    Anticancer Res; 2018 Nov; 38(11):6171-6180. PubMed ID: 30396934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer.
    Jung M; Park KH; Kim HM; Kim TS; Zhang X; Park SM; Beom SH; Kim HS; Cheong JH; Chung HC; Soong J; Lin SC; Rha SY
    Gastric Cancer; 2019 Nov; 22(6):1153-1163. PubMed ID: 31098863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear localization of the CK2α-subunit correlates with poor prognosis in clear cell renal cell carcinoma.
    Rabjerg M; Guerra B; Oliván-Viguera A; Mikkelsen ML; Köhler R; Issinger OG; Marcussen N
    Oncotarget; 2017 Jan; 8(1):1613-1627. PubMed ID: 27906674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Casein kinase 2 inhibitor CX-4945 elicits an anti-Warburg effects through the downregulation of TAp73 and inhibits gastric tumorigenesis.
    Tang S; Yuan Y; Liu Z; He Y; Pan D
    Biochem Biophys Res Commun; 2020 Oct; 530(4):686-691. PubMed ID: 32771361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of casein kinase 2 prevents growth of human osteosarcoma.
    Takahashi K; Setoguchi T; Tsuru A; Saitoh Y; Nagano S; Ishidou Y; Maeda S; Furukawa T; Komiya S
    Oncol Rep; 2017 Feb; 37(2):1141-1147. PubMed ID: 27959425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines.
    Hwang DW; So KS; Kim SC; Park KM; Lee YJ; Kim SW; Choi CM; Rho JK; Choi YJ; Lee JC
    Pancreas; 2017 Apr; 46(4):575-581. PubMed ID: 28196025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
    Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
    So KS; Rho JK; Choi YJ; Kim SY; Choi CM; Chun YJ; Lee JC
    Anticancer Res; 2015 Mar; 35(3):1537-42. PubMed ID: 25750308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
    Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
    Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.
    Bollacke A; Nienberg C; Borgne ML; Jose J
    J Pharm Biomed Anal; 2016 Mar; 121():253-260. PubMed ID: 26786382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity.
    Masłyk M; Janeczko M; Martyna A; Kubiński K
    Mol Cell Biochem; 2017 Nov; 435(1-2):193-196. PubMed ID: 28501934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.
    Trembley JH; Unger GM; Tobolt DK; Korman VL; Wang G; Ahmad KA; Slaton JW; Kren BT; Ahmed K
    Mol Cell Biochem; 2011 Oct; 356(1-2):21-35. PubMed ID: 21761204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.
    Ruggeri E; Frezzato F; Mouawad N; Pizzi M; Scarmozzino F; Capasso G; Trimarco V; Quotti Tubi L; Cellini A; Cavarretta CA; Ruocco V; Serafin A; Angotzi F; Danesin N; Manni S; Facco M; Piazza F; Trentin L; Visentin A
    Front Immunol; 2024; 15():1393485. PubMed ID: 38807597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of CX-4945 binding to human protein kinase CK2.
    Ferguson AD; Sheth PR; Basso AD; Paliwal S; Gray K; Fischmann TO; Le HV
    FEBS Lett; 2011 Jan; 585(1):104-10. PubMed ID: 21093442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
    Wińska P; Skierka K; Łukowska-Chojnacka E; Koronkiewicz M; Cieśla J; Bretner M
    Anticancer Res; 2018 Aug; 38(8):4617-4627. PubMed ID: 30061228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
    So KS; Kim CH; Rho JK; Kim SY; Choi YJ; Song JS; Kim WS; Choi CM; Chun YJ; Lee JC
    PLoS One; 2014; 9(12):e114000. PubMed ID: 25486409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
    Bian Y; Han J; Kannabiran V; Mohan S; Cheng H; Friedman J; Zhang L; VanWaes C; Chen Z
    Int J Biol Sci; 2015; 11(4):411-22. PubMed ID: 25798061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond.
    Kim J; Kim SH
    Arch Pharm Res; 2012 Aug; 35(8):1293-6. PubMed ID: 22941473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.